Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/41937
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Decoster, L. | - |
dc.contributor.author | Aftimos, P. G. | - |
dc.contributor.author | Rottey, S. | - |
dc.contributor.author | Prenen, H. | - |
dc.contributor.author | Collignon, J. J. | - |
dc.contributor.author | MEBIS, Jeroen | - |
dc.contributor.author | Canon, J-L. | - |
dc.contributor.author | Fastenaekels, V. | - |
dc.contributor.author | Cappoen, N. | - |
dc.contributor.author | Joris, S. R. | - |
dc.contributor.author | De Greve, J. | - |
dc.date.accessioned | 2023-12-15T08:27:48Z | - |
dc.date.available | 2023-12-15T08:27:48Z | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-12-15T07:41:10Z | - |
dc.identifier.citation | ANNALS OF ONCOLOGY, 34 , p. S262 | - |
dc.identifier.uri | http://hdl.handle.net/1942/41937 | - |
dc.description.abstract | Background: The Belgian Precision initiative aims to implement tumor-agnostic NGS in advanced cancer patients (pts) and enhance access to genotype-matching drugs. The current study aimed to investigate the efficacy of afatinib in advanced pre-treated solid cancers with an EGFR (excluding non-small cell lung cancer (NSCLC)), HER2 or HER3 mutation. | - |
dc.description.sponsorship | Kom op tegen kanker | - |
dc.publisher | ELSEVIER | - |
dc.subject.other | Interests, Personal, Full or part-time Employment: CDR-Life | - |
dc.subject.other | Other, Personal, Project Lead: CDR-Life L Borras: Financial Interests, Personal, Full or part-time Employment: CDR-Life | - |
dc.subject.other | Financial Interests, Personal, Leadership Role: CDR-Life | - |
dc.subject.other | Financial Interests, Personal, Stocks/Shares: CDR-Life S Biswas: Financial Interests, Personal, Full or part-time Employment: CDR-Life R Leidner: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb | - |
dc.subject.other | Financial Interests, Personal, Project Lead: Bristol Myers Squibb, Incycte E Calvo: Financial Interests, Personal, Advisory Board: Adcendo, Amunix, Anaveon, AstraZeneca, BMS, Janssen, MonTa, MSD, Nanobiotix, Nouscom, Novartis, Servier, Tar- gImmune, T-knife, Chugai, Elevation Oncology, Ellipses Pharmacy, SyneosHealth, Genmab, Diac- curate | - |
dc.subject.other | Financial Interests, Personal, Invited Speaker: OncoDNA, PharmaMar, Roche/Genentech | - |
dc.subject.other | Financial Interests, Personal, Full or part-time Employment, Director, Clinical Research: HM Hospi- tales Group | - |
dc.subject.other | Financial Interests, Personal, Full or part-time Employment, Medical Oncologist Clinical Investigator Director, Clinical Research: START Madrid -CIOCC (Centro Integral Oncológico Clara Campal) | - |
dc.subject.other | Financial Interests, Personal, Member of Board of Directors, External Independent member of Board of Directors: PharmaMar | - |
dc.subject.other | Financial Interests, Personal, Ownership Interest: START, Oncoart Associated | - |
dc.subject.other | Financial Interests, Personal, Steering Committee Member, Member of Data Monitoring Committee: BeiGene, Sanofi, Merus | - |
dc.subject.other | Financial Interests, Personal, Steering Committee Member: Novartis | - |
dc.subject.other | Non-Financial Interests, Other, Non-for-profit Foundation President and co-founder: INTHEOS (Investigational Therapeutics in Oncological Sciences) non-for-profit Foundation | - |
dc.subject.other | Non- Financial Interests, Advisory Role: PsiOxus | - |
dc.subject.other | Non-Financial Interests, Other, Chair of the Independent | - |
dc.title | Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study | - |
dc.type | Journal Contribution | - |
local.bibliographicCitation.conferencedate | OCT 20-24, 2023 | - |
local.bibliographicCitation.conferencename | Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) | - |
local.bibliographicCitation.conferenceplace | Barcelona, SPAIN | - |
dc.identifier.spage | S262 | - |
dc.identifier.volume | 34 | - |
local.format.pages | 1 | - |
local.bibliographicCitation.jcat | M | - |
local.publisher.place | RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
dc.identifier.doi | 10.1016/j.annonc.2023.09.2924 | - |
dc.identifier.isi | 001087480200196 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Decoster, L.] Univ Ziekenhuis Brussel, UZ Brussel, Dept Med Oncol, Jette, Belgium. | - |
local.description.affiliation | [Aftimos, P. G.] Inst Jules Bordet, Clin Trials Conduct Unit, Anderlecht, Belgium. | - |
local.description.affiliation | [Rottey, S.] Univ Hosp Ghent, Dept Med Oncol, UZ Gent, Ghent, Belgium. | - |
local.description.affiliation | [Prenen, H.] Univ Hosp Antwerp, UZA, Oncol Dept, Edegem, Belgium. | - |
local.description.affiliation | [Collignon, J. J.] CHU Liege Sart Tilman, Serv Oncol, Dept Med Oncol, Liege, Belgium. | - |
local.description.affiliation | [Mebis, J.] Jesse Ziekenhuis, Dept Med Oncol, Campus Virga Jesse, Hasselt, Belgium. | - |
local.description.affiliation | [Canon, J-L.] GHdC Grand Hop Charleroi, Dept Oncol Hematol, Site Notre Dame, Charleroi, Belgium. | - |
local.description.affiliation | [Fastenaekels, V.; Cappoen, N.; Joris, S. R.] Univ Ziekenhuis Brussel, UZ Brussel, Med Oncol, Jette, Belgium. | - |
local.description.affiliation | [De Greve, J.] Vrije Univ Brussel, Med Oncol Dept, Fac Med & Pharm, Brussels, Belgium. | - |
local.uhasselt.international | no | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | Decoster, L.; Aftimos, P. G.; Rottey, S.; Prenen, H.; Collignon, J. J.; MEBIS, Jeroen; Canon, J-L.; Fastenaekels, V.; Cappoen, N.; Joris, S. R. & De Greve, J. (2023) Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. In: ANNALS OF ONCOLOGY, 34 , p. S262. | - |
item.contributor | Decoster, L. | - |
item.contributor | Aftimos, P. G. | - |
item.contributor | Rottey, S. | - |
item.contributor | Prenen, H. | - |
item.contributor | Collignon, J. J. | - |
item.contributor | MEBIS, Jeroen | - |
item.contributor | Canon, J-L. | - |
item.contributor | Fastenaekels, V. | - |
item.contributor | Cappoen, N. | - |
item.contributor | Joris, S. R. | - |
item.contributor | De Greve, J. | - |
crisitem.journal.issn | 0923-7534 | - |
crisitem.journal.eissn | 1569-8041 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors_ A phase II Belgian precision study.pdf | Published version | 71.86 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.